Introduction: Dihydroartemisinin-piperaquine (DHA-PQP) is a well-established first-line therapy for uncomplicated malaria. However, resistance to this combination has emerged throughout Southeast Asia, resulting in substantially reduced treatment efficacy1,2. To counter the development of resistance, novel triple combinations of antimalarials have been trialed, adding another long acting antimalarial to a current antimalarial combination. One such combination is […]
